Xiaoning Li

Xiaoning Li

Auto-generated profile, based on publicly available information

Xiaoning Li

School of Foreign Languages, Nanning Normal University, 3 Hexing Road, Qingxiu District, Nanning 530299, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YZYimin Zhang
Yimin Zhang
JCJingqin Chen
Jingqin Chen
WFWenxuan Fang
Wenxuan Fang
KLKaoyun Liang
Kaoyun Liang
XLXiaoning Li
Xiaoning Li
Xueni WangXueni Wang
Xueni Wang

26 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Xueni WangXueni Wang
Xueni Wang
QZqian Zhou
qian Zhou
XLXiaoning Li
Xiaoning Li
XGxia gan
xia gan
PLPeng Liu
Peng Liu
Yonghong LiuYonghong Liu
Yonghong Liu
Prostate cancer is a common cancer in elderly males. Significant progress has been made in the drug therapies for prostate cancer in recent years. However, side effects are still problems that have not been overcome by the currently used anti-prostate cancer drugs. Novel technologies can be applied to reduce or even eliminate the side effects of drugs. An aptamer may be a sequence of nucleic acids or peptides that can specifically recognize proteins or cells. Taking advantage of this feature, scientists have designed aptamer–drug delivery systems for the development of anti-prostate cancer agents. Theoretically, these aptamer–drug delivery systems can specifically recognize prostate cancer cells and then induce cell death without attacking normal cells. We collected the relevant literature in this field and found that at least nine compounds have been prepared as aptamer–drug delivery systems to evaluate their precise anti-prostate cancer effects. However, the currently studied aptamer–drug delivery systems have not yet entered the market due to defects. Here, we analyze the published data, summarize the characteristics of these delivery systems, and propose ways to promote their application, thus promoting the development of the aptamer–drug delivery systems against prostate cancer.